MedPath

Hydrocortisone as co-treatment to prevent neuropsychiatric adverse effects of dexamethasone.

Phase 1
Conditions
europsychiatric adverse effects which can be caused by dexamethasone. For example delirium, anxiety, depression, mania and psychosis. But also cognitive impairment and sleep disturbance.
Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Registration Number
EUCTR2017-003705-17-NL
Lead Sponsor
MC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
180
Inclusion Criteria

Cranial glioma, meningioma or brain metastasis scheduled to undergo surgery (resection)
Minimal dose of peri-operative cumulative dexamethasone exposure of 24mg or more in 6 days
=18 years
Good clinical condition; KPS = 70 (see attachments 1)
Life expectancy = 6 months

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 130
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

Non-native speakers of Dutch or insufficient command of the Dutch language
Patients that are unable to overview consequences of trial participation
Patients with aphasia
Patients that are not able to fill in the questionnaires because of cognitive impairments at the discretion of the physician
Patients with psychiatric diseases or neurological deficits that interfere with the study to the judgement of treating physician

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath